

# CITATION REPORT

List of articles citing

The selectivity and potency of the new PDE5 inhibitor TPN72

DOI: 10.1111/jsm.12285

Journal of Sexual Medicine, 2013, 10, 2790-7.

**Source:** <https://exaly.com/paper-pdf/56074196/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
13	Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. <i>Acta Pharmacologica Sinica</i> , <b>2015</b> , 36, 1528-36	8	13
12	Characterization of TPN729 metabolites in humans using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2016</b> , 117, 217-26	3.5	10
11	Innovative trends and perspectives for erectile dysfunction treatment: A systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , <b>2016</b> , 14, 84-93	1.7	26
10	Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2017</b> , 32, 311-330	5.6	20
9	Simultaneous determination of TPN729 and its five metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 151, 91-105	3.5	1
8	Pharmacotherapy for erectile dysfunction in diabetic males. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1345-1356	4	0
7	Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist. <i>ACS Chemical Neuroscience</i> , <b>2020</b> , 11, 1726-1739	5.7	12
6	Solid scintillation analysis. <b>2020</b> , 899-1045		2
5	Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor. <i>Acta Pharmacologica Sinica</i> , <b>2021</b> , 42, 482-490	8	4
4	Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 821-834	4	3
3	Identification of a Cyclic Dinucleotide Phosphodiesterase Inhibitor. <i>ACS Infectious Diseases</i> , <b>2021</b> , 7, 309-317	3.5	2
2	Treatment of Erectile Disorder. <b>2017</b> , 187-201		
1	Absorption, distribution, metabolism, and excretion of [C]TPN729 after oral administration to rats.. <i>Xenobiotica</i> , <b>2022</b> , 1-28	2	1